Literature DB >> 29535156

Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.

Michael D Raleigh1, Megan Laudenbach2, Federico Baruffaldi2, Samantha J Peterson2, Michaela J Roslawski2, Angela K Birnbaum2, F Ivy Carroll2, Scott P Runyon2, Scott Winston2, Paul R Pentel2, Marco Pravetoni2.   

Abstract

Heroin and oxycodone abuse occurs over a wide range of drug doses and by various routes of administration characterized by differing rates of drug absorption. The current study addressed the efficacy of a heroin vaccine [morphine hapten conjugated to keyhole limpet hemocyanin (M-KLH)] or oxycodone vaccine [oxycodone hapten conjugated to keyhole limpet hemocyanin (OXY-KLH)] for reducing drug distribution to brain after intravenous heroin or oxycodone, or subcutaneous oxycodone. Rats immunized with M-KLH or keyhole limpet hemocyanin (KLH) control received an intravenous bolus dose of 0.26 or 2.6 mg/kg heroin. Vaccination with M-KLH increased retention of heroin and its active metabolites 6-acetylmorphine (6-AM) and morphine in plasma compared with KLH controls, and reduced total opioid (heroin + 6-AM + morphine) distribution to brain but only at the lower heroin dose. Immunization also protected against respiratory depression at the lower heroin dose. Rats immunized with OXY-KLH or KLH control received 0.22 or 2.2 mg/kg oxycodone intravenously, the molar equivalent of the heroin doses. Immunization with OXY-KLH significantly reduced oxycodone distribution to brain after either oxycodone dose, although the magnitude of effect of immunization at the higher oxycodone dose was small (12%). By contrast, vaccination with OXY-KLH was more effective when oxycodone was administered subcutaneously rather than intravenously, reducing oxycodone distribution to brain by 44% after an oxycodone dose of 2.3 mg/kg. Vaccination also reduced oxycodone-induced antinociception. These data suggest that the efficacy of OXY-KLH and M-KLH opioid vaccines is highly dependent upon opioid dose and route of administration.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29535156      PMCID: PMC5884377          DOI: 10.1124/jpet.117.247049

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

1.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

2.  Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat.

Authors:  M I Bazin-Redureau; C B Renard; J M Scherrmann
Journal:  J Pharm Pharmacol       Date:  1997-03       Impact factor: 3.765

3.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

4.  The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Authors:  Megan Laudenbach; Federico Baruffaldi; Jeffrey S Vervacke; Mark D Distefano; Philip J Titcombe; Daniel L Mueller; Noah J Tubo; Thomas S Griffith; Marco Pravetoni
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

5.  Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.

Authors:  Irina Esterlis; Jonas O Hannestad; Evgenia Perkins; Frederic Bois; D Cyril D'Souza; Rachel F Tyndale; John P Seibyl; Dorothy M Hatsukami; Kelly P Cosgrove; Stephanie S O'Malley
Journal:  Am J Psychiatry       Date:  2013-04       Impact factor: 18.112

6.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

7.  A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.

Authors:  Benito Anton; Philippe Leff
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

8.  The Andalusian trial on heroin-assisted treatment: a 2 year follow-up.

Authors:  Eugenia Oviedo-Joekes; Joan C March; Manuel Romero; Emilio Perea-Milla
Journal:  Drug Alcohol Rev       Date:  2010-01

9.  Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.

Authors:  Miroslav Backonja; Lynn R Webster; Beatrice Setnik; Almasa Bass; Kenneth W Sommerville; Kyle Matschke; Bimal K Malhotra; Gernot Wolfram
Journal:  Am J Drug Alcohol Abuse       Date:  2016-05-21       Impact factor: 3.829

10.  Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

Authors:  M D Raleigh; S J Peterson; M Laudenbach; F Baruffaldi; F I Carroll; S D Comer; H A Navarro; T L Langston; S P Runyon; S Winston; M Pravetoni; P R Pentel
Journal:  PLoS One       Date:  2017-12-01       Impact factor: 3.240

View more
  17 in total

1.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

Review 2.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

3.  Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Authors:  Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

4.  National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)-August 6/7, 2019.

Authors:  David T Yeung; Kristopher J Bough; Jill R Harper; Gennady E Platoff
Journal:  J Med Toxicol       Date:  2019-12-18

5.  Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation.

Authors:  F Baruffaldi; M D Raleigh; S J King; M J Roslawski; A K Birnbaum; C Hassler; F I Carroll; S P Runyon; S Winston; P R Pentel; M Pravetoni
Journal:  Mol Pharm       Date:  2019-05-14       Impact factor: 4.939

6.  Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats.

Authors:  Carly Baehr; April Huseby Kelcher; Aaron Khaimraj; Dana E Reed; Sujata G Pandit; David AuCoin; Saadyah Averick; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2020-09-26       Impact factor: 4.030

Review 7.  Immunopharmacotherapies for Treating Opioid Use Disorder.

Authors:  Matthew L Banks; Margaret E Olson; Kim D Janda
Journal:  Trends Pharmacol Sci       Date:  2018-11       Impact factor: 14.819

8.  Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins.

Authors:  Federico Baruffaldi; April Huseby Kelcher; Megan Laudenbach; Valeria Gradinati; Ajinkya Limkar; Michaela Roslawski; Angela Birnbaum; Andrew Lees; Carla Hassler; Scott Runyon; Marco Pravetoni
Journal:  Mol Pharm       Date:  2018-10-10       Impact factor: 4.939

9.  Prophylactic vaccination protects against the development of oxycodone self-administration.

Authors:  Jacques D Nguyen; Candy S Hwang; Yanabel Grant; Kim D Janda; Michael A Taffe
Journal:  Neuropharmacology       Date:  2018-06-22       Impact factor: 5.250

10.  Synthesis and immunological effects of C14-linked 4,5-epoxymorphinan analogues as novel heroin vaccine haptens.

Authors:  Eugene S Gutman; Thomas C Irvin; J Brian Morgan; Rodell C Barrientos; Oscar B Torres; Zoltan Beck; Gary R Matyas; Arthur E Jacobson; Kenner C Rice
Journal:  RSC Chem Biol       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.